Role in PharmNovo: Scientific advisor.
University: Galway Neuroscience Centre.
Resumé: David Finn is Professor of Pharmacology and Therapeutics, Science Foundation Ireland Principal Investigator and Co-Founder and Co-Director of the Centre for Pain Research (link) at the National University of Ireland (NUI) Galway. Professor Finn graduated with a BSc (Hons) in Biotechnology from NUI Galway in 1997 and a PhD in Neuroscience from the University of Bristol in 2001. From 2001 to 2004, Professor Finn worked as a Post-doctoral Research Fellow at the Institute of Neuroscience, University of Nottingham. In 2004, he was appointed to a Lectureship in the Department of Physiology, NUI Galway, and to a Personal Professorship in Pharmacology and Therapeutics in 2014. Professor Finn’s research focuses on the understanding of the neurobiology and treatment of pain and psychiatric disorders including anxiety and depression.
Professor Finn is Past-President of the Irish Pain Society and is currently President-Elect of the International Cannabinoid Research Society. He is also a member of the Task Forces of both the International Association for the Study of Pain and the European Pain Federation on Cannabis and Cannabinoids for Chronic Pain, and he sits on the Scientific Advisory Panel of the European College of Neuropsychopharmacology as well as the Editorial Boards of the Journal of Psychopharmacology, Brain Research and Frontiers in Neuropharmacology (link).
Member of:
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read morePharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read moreAs the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more